Department of Functional Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
CNS Neurosci Ther. 2022 Dec;28(12):2163-2171. doi: 10.1111/cns.13958. Epub 2022 Sep 7.
Previous studies have reported the effects of age and disease duration on the efficacy of subthalamic nuclei deep brain stimulation (STN-DBS) of Parkinson's disease (PD) patients. However, available data involving these issues are not consistent. In particular, the effect of age and disease duration on the initial efficacy of STN-DBS has not been established.
A total of 51 patients with PD treated with bilateral STN-DBS were involved in the present study. They received clinical symptom evaluation during the preoperative, initial, and chronic stages of surgery. The correlations between age when undergoing surgery/age at disease onset/disease duration and outcomes of STN-DBS were measured.
The preoperative levodopa response was negatively associated with age. During the initial stage, the age when undergoing surgery and age at disease onset were negatively correlated with the effect on bradykinesia, with better symptom control of general symptoms in long-term disease patients. Similarly, patients with an early time of surgery and disease onset and long-term disease duration showed better control of bradykinesia and axial symptoms at the chronic stage. Furthermore, a long-term disease duration and early disease onset benefited from an increase of therapeutic efficacy in general, rigid, and axial symptoms with STN-DBS after a long period. Nevertheless, patients with late disease onset achieved a better relief of stigma.
Age and disease durations played a unique role in controlling the symptoms of PD patients treated with STN-DBS. These results may contribute to patient selection and adjustments of expectations of surgery, based on the age, disease duration, and different symptoms.
先前的研究报告了年龄和疾病持续时间对帕金森病(PD)患者丘脑底核深部脑刺激(STN-DBS)疗效的影响。然而,涉及这些问题的现有数据并不一致。特别是,年龄和疾病持续时间对 STN-DBS 初始疗效的影响尚未确定。
本研究共纳入 51 例接受双侧 STN-DBS 治疗的 PD 患者。他们在手术前、初始和慢性阶段接受了临床症状评估。测量了手术时年龄/发病年龄/疾病持续时间与 STN-DBS 结果之间的相关性。
术前左旋多巴反应与年龄呈负相关。在初始阶段,手术时年龄和发病年龄与运动迟缓的疗效呈负相关,长期疾病患者的一般症状控制更好。同样,手术和发病时间较早且疾病持续时间较长的患者在慢性阶段表现出更好的运动迟缓和轴性症状控制。此外,长期疾病持续时间和早期发病受益于 STN-DBS 治疗后一般、僵硬和轴性症状的治疗效果增加。然而,晚期发病的患者在获得更好的缓解耻辱感方面表现更好。
年龄和疾病持续时间在控制接受 STN-DBS 治疗的 PD 患者的症状方面发挥了独特的作用。这些结果可能有助于根据年龄、疾病持续时间和不同症状选择患者并调整对手术的期望。